Immuron vs Taysha Gene Therapies
Taysha Gene Therapies is the larger business, with $9.8m of revenue in fiscal 2025 against $5.2m for Immuron (1.9 times as much). Taysha Gene Therapies grew faster (17.3% against 10.9%). Immuron kept more of each dollar of sales as profit: a net margin of -47.7% against -1115.3%. Immuron carries less debt relative to equity (0.0% against 20.3%).
| Latest fiscal year | ImmuronIMRN, 2026 | Taysha Gene TherapiesTSHA, 2025 |
|---|---|---|
| Revenue | $5.2m | $9.8m |
| Revenue growth | 10.9% | 17.3% |
| Net income | −$2.5m | −$109m |
| Operating margin | -49.9% | -1130.6% |
| Net margin | -47.7% | -1115.3% |
| Return on equity | -38.4% | -68.5% |
| Free cash flow | −$2.2m | −$93.8m |
| Cash | $6.2m | $320m |
| Total debt | $0 | $50.1m |
| Debt to equity | 0.0% | 20.3% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 99 |
| Market value | $6.7m | $1.32bn |
| Price vs our value range | — | — |
| Moat score | — | — |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 12 sales |